PMID- 35454834
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 14
IP  - 8
DP  - 2022 Apr 11
TI  - Pancreaticoduodenectomy Is the Best Surgical Procedure for Zollinger-Ellison 
      Syndrome Associated with Multiple Endocrine Neoplasia Type 1.
LID - 10.3390/cancers14081928 [doi]
LID - 1928
AB  - AIM: The aim of this research was to evaluate the long-term outcome of 
      pancreaticoduodenectomy (PD) versus other duodenopancreatic resections (non-PD) 
      for the surgical treatment of the Zollinger-Ellison syndrome (ZES) in patients 
      with multiple endocrine neoplasia type 1 (MEN1). METHODS: Prospectively recorded 
      patients with biochemically confirmed MEN1-ZES who underwent duodenopancreatic 
      surgery were retrospectively analyzed in terms of clinical characteristics, 
      complications, cure rate, and long-term morbidity, including quality of life 
      assessment (EORTC QLQ-C30). RESULTS: 35 patients (16 female, 19 male) with 
      MEN1-ZES due to duodenopancreatic gastrinomas with a median age of 42 (range 
      30-74) years were included. At the time of diagnosis, 28 (80%) gastrinomas were 
      malignant, but distant metastases were only present in one (3%) patient. Eleven 
      patients (31.4%) underwent pancreatoduodenectomy (PD) as the initial procedure, 
      whereas 24 patients underwent non-PD resections involving duodenotomy with 
      gastrinoma excision, enucleation of the pNEN from the head of the pancreas, and 
      peripancreatic lymphadenectomy, either with or without distal pancreatectomy 
      (i.e., either Thompson procedure, n = 12, or DUODX, n = 12). There was no 
      significant difference in perioperative morbidity and mortality between the two 
      groups (p >/= 0.05). One (9%) patient of the PD group required reoperation for 
      recurrent or metastatic ZES compared to eight (22.8%) patients of the non-PD 
      resection groups. After a median follow-up time of 134 months (range 6-480) nine 
      of 11 (82%) patients in the PD group, two of 12 (16%) patients in the Thompson 
      procedure group, and three of 12 (25%) patients in the DUODX group had normal 
      serum gastrin levels. In addition, the global health QoLScore was better in the 
      PD group (76.9) compared to the Thompson procedure (57.4) and DUODX (59.5) 
      groups. CONCLUSIONS: Initial PD seems to be the superior surgical procedure for 
      MEN1-ZES, resulting in a long-term cure rate of about 80%, fewer 
      duodenopancreatic reoperations, and an acceptable quality of life.
FAU - Kong, Weihua
AU  - Kong W
AUID- ORCID: 0000-0003-4111-7523
AD  - Department of Surgery, Philipps-University, 35041 Marburg, Germany.
FAU - Albers, Max Benjamin
AU  - Albers MB
AD  - Department of Surgery, Philipps-University, 35041 Marburg, Germany.
FAU - Manoharan, Jerena
AU  - Manoharan J
AD  - Department of Surgery, Philipps-University, 35041 Marburg, Germany.
FAU - Goebel, Joachim Nils
AU  - Goebel JN
AD  - Department of Gastroenterology, Division of Endocrinology and Diabetology, 
      Philipps-University, 35043 Marburg, Germany.
FAU - Kann, Peter Herbert
AU  - Kann PH
AD  - Department of Gastroenterology, Division of Endocrinology and Diabetology, 
      Philipps-University, 35043 Marburg, Germany.
FAU - Jesinghaus, Moritz
AU  - Jesinghaus M
AD  - Department of Pathology, Philipps-University, 35043 Marburg, Germany.
FAU - Bartsch, Detlef Klaus
AU  - Bartsch DK
AD  - Department of Surgery, Philipps-University, 35041 Marburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20220411
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9032426
OTO - NOTNLM
OT  - MEN1
OT  - ZES
OT  - gastrinoma
OT  - pancreaticoduodenectomy
OT  - surgery
COIS- The authors declare no conflict of interest.
EDAT- 2022/04/24 06:00
MHDA- 2022/04/24 06:01
PMCR- 2022/04/11
CRDT- 2022/04/23 01:05
PHST- 2022/02/16 00:00 [received]
PHST- 2022/04/06 00:00 [revised]
PHST- 2022/04/07 00:00 [accepted]
PHST- 2022/04/23 01:05 [entrez]
PHST- 2022/04/24 06:00 [pubmed]
PHST- 2022/04/24 06:01 [medline]
PHST- 2022/04/11 00:00 [pmc-release]
AID - cancers14081928 [pii]
AID - cancers-14-01928 [pii]
AID - 10.3390/cancers14081928 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Apr 11;14(8):1928. doi: 10.3390/cancers14081928.